Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 115-122

  Schiffelers, Raymond M ^a   Koning, Gerben A ^a   Ten Hagen, Timo L M ^b   Fens, Marcel H A M ^a   Schraa, Astrid J ^c   Janssen, Adriënne P C A ^a   Kok, Robbert J ^d   Molema, Grietje ^c,d   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Alpha v beta 3 integrin; Angiogenesis; Doxorubicin; Liposomes; RGD

Indexed keywords

CELLS; MICROSCOPIC EXAMINATION; TUMORS;

ANGIOGENESIS;

CONTROLLED DRUG DELIVERY;

ALPHA5 INTEGRIN; BETA3 INTEGRIN; DOXORUBICIN; LIPOID; LIPOSOME; MACROGOL; ANTINEOPLASTIC ANTIBIOTIC; EXCIPIENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CELL PROLIFERATION; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD FLOW; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; NEOPLASM; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ENDOTHELIUM, VASCULAR; EXCIPIENTS; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; REGIONAL BLOOD FLOW; TISSUE DISTRIBUTION;

EID: 0141990623     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00240-2     Document Type: Conference Paper

References (21)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:(6801):2000;249-257.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:(1):1995;27-31.
3. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52:(2):2000;237-268.
4. Scappaticci F.A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20:(18):2002;3906-3927.
5. Chavakis E., Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol. 22:(6):2002;887-893.
6. Jimenez B., Volpert O.V. Mechanistic insights on the inhibition of tumor angiogenesis. J. Mol. Med. 78:(12):2001;663-672.
7. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8:(9):2002;918-921.
8. Kumar C.C., Armstrong L., Yin Z., Malkowski M., Maxwell E., Ling H., Yaremko B., Liu M., Varner J., Smith E.M., Neustadt B., Nechuta T. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv. Exp. Med. Biol. 476:2000;169-180.
9. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., Goodman S.L., Kessler H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42:(16):1999;3033-3040.
10. Kok R.J., Schraa A.J., Bos E.J., Moorlag H.E., Asgeirsdottir S.A., Everts M., K Meijer D., Molema G. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug. Chem. 13:(1):2002;128-135.
11. Boerman O.C., Storm G., Oyen W.J., van Bloois L., van der Meer J.W., Claessens R.A., Crommelin D.J., Corstens F.H. Sterically stabilized liposomes labeled with indium-111 to image focal infection. J. Nucl. Med. 36:(9):1995;1639-1644.
12. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta. 1151:(2):1993;201-215.
13. Koning G.A., Gorter A., Scherphof G.L., Kamps J.A. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br. J. Cancer. 80:(11):1999;1718-1725.
14. Rouser G., Fleisner S., Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:(5):1970;494-496.
15. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:(1):1997;66-75.
16. Papenfuss H.D., Gross J.F., Intaglietta M., Treese F.A. A transparent access chamber for the rat dorsal skin fold. Microvasc. Res. 18:(3):1979;311-318.
17. Sutcliffe-Goulden J.L., O'Doherty M.J., Marsden P.K., Hart I.R., Marshall J.F., Bansal S.S. Rapid solid phase synthesis and biodistribution of (18)F-labelled linear peptides. Eur. J. Nucl. Med. Mol. Imaging. 29:(6):2002;754-759.
18. Singh B., Rawlings N., Kaur A. Expression of integrin alphavbeta3 in pig, dog and cattle. Histol. Histopathol. 16:2001;1037-1046.
19. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:(1-2):2000;271-284.
20. Huang S.K., Mayhew E., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C26 colon carcinoma. Cancer Res. 52:(24):1992;6774- 6781.
21. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.-D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:(24):1991;11460-11464.